AVENUE SOLUTIONS

Lobbying for GENENTECH USA, INC. · Biotechnology

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Health Issues

Issues related to 340b drug pricing program; Expiring healthcare extenders

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.